Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Liquid biopsies for bladder cancer
Douglas Ward
,
Richard Bryan
Cancer and Genomic Sciences
Research output
:
Contribution to journal
›
Editorial
›
peer-review
35
Downloads (Pure)
Overview
Fingerprint
Research output
(6)
Projects
(1)
Fingerprint
Dive into the research topics of 'Liquid biopsies for bladder cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bladder Cancer
100%
Tumor DNA
100%
Liquid Biopsy
100%
Urinary Cell-free DNA
100%
Circulating Tumor DNA (ctDNA)
66%
Droplet Digital PCR (ddPCR)
66%
Disease Progression
33%
Urothelial Bladder Cancer
33%
Cell-free DNA (cfDNA)
33%
Tumor Grade
33%
Recurrent Disease
33%
Tumor Size
33%
Patient Management
33%
Mutant Cells
33%
Tumor Stage
33%
Cystectomy
33%
Cell Pellet
33%
Mutant Alleles
33%
Non-muscle Invasive Bladder Cancer (NMIBC)
33%
Cystoscopy
33%
Nontumor
33%
Multiplexing
33%
FGFR3 mutation
33%
Non-invasive Detection
33%
Predictive Biomarker
33%
Next-generation Sequencing
33%
Proof of Concept Study
33%
Urinary Biomarkers
33%
Patient Journey
33%
Rare mutant
33%
PIK3CA mutation
33%
Mutation Panel
33%
Urinary Cells
33%
Medicine and Dentistry
Urinary System
100%
Bladder Cancer
100%
Liquid Biopsy
100%
Cell-Free DNA
66%
Neoplasm
50%
Biological Marker
33%
Circulating Tumor DNA
33%
Droplet Digital Polymerase Chain Reaction
33%
Patient Care
16%
Allele
16%
Recurrent Disease
16%
Disease Exacerbation
16%
Weakness
16%
Cancer Staging
16%
Cystectomy
16%
Cystoscopy
16%
Next Generation Sequencing
16%
Fibroblast Growth Factor Receptor 3
16%
Multiplexing
16%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
100%
Droplet Digital Polymerase Chain Reaction
100%
Blood Plasma
50%
Allele
50%
Tumor Volume
50%
Cell Mutant
50%
Cancer Staging
50%
Fibroblast Growth Factor Receptor 3
50%
Next Generation Sequencing
50%
Pharmacology, Toxicology and Pharmaceutical Science
Bladder Cancer
100%
Neoplasm
100%
Biological Marker
66%
Circulating Tumor DNA
66%
Recurrent Disease
33%
Disease Exacerbation
33%
Cancer Staging
33%
Weakness
33%
Fibroblast Growth Factor Receptor 3
33%
Immunology and Microbiology
Droplet Digital Polymerase Chain Reaction
100%
Blood Plasma
50%
Allele
50%
Cell Mutant
50%
Cancer Staging
50%
Tumor Volume
50%
Next Generation Sequencing
50%
Fibroblast Growth Factor Receptor 3
50%